NAV

Andusomeran

Identification

Summary

Andusomeran is an mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus, including the XBB.1.5 subvariant.

Brand Names
Spikevax
Generic Name
Andusomeran
DrugBank Accession Number
DB18227
Background

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.3,4,5 It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • COVID-19 mRNA vaccine, monovalent (XBB.1.5 Variant)
  • CX-038839 Omicron (XBB.1.5)
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Andusomeran is indicated for the prevention of COVID-19 caused by SARS-CoV-2.3,4 It is intended to elicit protection against the Omicron XBB.1.5 subvariant.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofCoronavirus disease 2019 (covid‑19)•••••••••••••••••••••
Prevention ofCoronavirus disease 2019 (covid‑19)•••••••••••••••••••••
Prevention ofNovel coronavirus infectious disease (covid-19)•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

The safety and efficacy of andusomeran are primarily inferred from studies of the original Spikevax vaccine (elasomeran) and a previously approved bivalent vaccine (elasomeran and imelasomeran).4

Mechanism of action

Moderna's COVID-19 mRNA vaccine is composed of synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2.1 The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell.2 Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to protection against SARS-CoV-2.4

Andusomeran is a COVID-19 mRNA vaccine that encodes for the pre-fusion stabilized S glycoprotein of the SARS-CoV-2 Omicron subvariant XBB.1.5 (containing mutations K982P and V983P) which is intended to elicit protection against this variant.4

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Moderna COVID-19 VaccineInjection, suspension25 ug/0.25mLIntramuscularModerna US, Inc.2023-09-11Not applicableUS flag
SpikevaxInjection, solution50 ug/0.5mLIntramuscularCatalent Indiana, LLC2023-09-11Not applicableUS flag
SpikevaxInjection, suspension50 ug/0.5mLIntramuscularModerna US, Inc.2023-09-11Not applicableUS flag
Spikevax XbB.1.5Injection0.1 mg / mLIntramuscularModerna Biopharma Canada Corporation2023-09-18Not applicableCanada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans

Chemical Identifiers

UNII
4F9QRS7ZV2
CAS number
2918977-08-7

References

General References
  1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH: An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 Jul 14. doi: 10.1056/NEJMoa2022483. [Article]
  2. Kaur SP, Gupta V: COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13. [Article]
  3. FDA Approved Drug Products: Spikevax (COVID-19 Vaccine, mRNA) suspension for injection for intramuscular use (Updated Sept 2023) [Link]
  4. Health Canada Product Monograph: Spikevax XBB.1.5 (monovalent COVID-19 vaccine, andusomeran) dispersion for intramuscular injection [Link]
  5. EMA EPAR: Spikevax (Moderna COVID-19 vaccine) [Link]
RxNav
2664725
Wikipedia
Moderna_COVID-19_vaccine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableActive Not RecruitingNot AvailableCoronavirus Disease 2019 (COVID‑19)1
Not AvailableRecruitingNot AvailableCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular25 ug/0.25mL
Injection, solutionIntramuscular50 ug/0.5mL
Injection, suspensionIntramuscular50 ug/0.5mL
SuspensionIntramuscular50 mcg
InjectionIntramuscular0.1 mg / mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at September 14, 2023 15:54 / Updated at December 06, 2023 04:53